Last reviewed · How we verify
OXYGEN
At a glance
| Generic name | OXYGEN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults (PHASE1)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- SMILE Trial - Imaging Sub-Study
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXYGEN CI brief — competitive landscape report
- OXYGEN updates RSS · CI watch RSS